Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ADC

Financiado

Cerrado

Next Generation Antibody Drug Conjugates for safer and more effective cancer the...

Next Generation Antibody Drug Conjugates for safer and more effective cancer therapies Oncolinx has developed a novel molecular platform allowing for non-invasive and highly effective cancer cures. The platform carries a killing drug (Azonafide), linked to an antibody, specifically targeting and destroying only mali... ver más

30/09/2016

GOLDSMITHS'

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

GOLDSMITHS' COLLEGE No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2016-09-30

SMEInst-05-2016-2017: Supporting innovative SMEs in the h...

I+D

Cerrada hace 8 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

GOLDSMITHS'

50.00K€ | Lider

Proyectos interesantes

DESARROLLO DE INMUNOTERAPIAS CONTRA EL CÁNCER...

Medical Technol...

Pharmaceutical...

676K€ Cerrado

AGAINST

Medical Technol...

Biotechnology

150K€ Cerrado

TAM-ADaCT

Medical Technol...

Biotechnology

150K€ Cerrado

BispecificsThatClick

Medical Technol...

Biotechnology

213K€ Cerrado

SPLITVAC

Medical Technol...

Data Science

173K€ Cerrado

ONCO-BOOST

Medical Technol...

Biotechnology

71K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 0 meses Fecha Inicio: 2016-09-06
Fecha Fin: 2016-09-30

Líder del proyecto

GOLDSMITHS' COLLEGE No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Oncolinx has developed a novel molecular platform allowing for non-invasive and highly effective cancer cures. The platform carries a killing drug (Azonafide), linked to an antibody, specifically targeting and destroying only malignant tumour cells. These molecular complexes are called Antibody Drug Conjugates (ADCs) and represent a strong, valid alternative to current chemotherapies. Oncolinx’s innovative linker/payload technology enables the Azonafide platform to perform a sensitive discrimination between healthy and cancer cells, thereby avoiding adverse side-effects of chemotherapy. ADCs enhance the effectiveness of a systemic treatment and have the advantage of targeting only tumour sites within the same therapy. Oncolinx’s drugs are effective against drug resistant cancers, as well as cancer stem cells (CSCs)—cells directly responsible for drug-resistance, metastasis, and relapse. In addition, Oncolinx’s technology activates the immune system against the tumour, which is an integral hallmark of durable responses. Although Oncolinx’s platform is designed to be adopted for drug-resistant breast cancers as first application, the Azonafide payload potency has been validated across all NCI-60 cell lines screening for different tumour types. The NCI-60 Human Tumour Cell Lines Screen also showed that the Azonafide payload, when conjugated with Oncolinx linker technology to specific antibodies, can kill up to 98.2% of cancer cells while remaining non-toxic to cells that do not express the antigen. NCI-60 screening has shown subnanomolar-picomolar potency across cancers (1x10-9M). While a variety of ADCs compound are currently developed and tested, only two ADCs have been approved so far. However, because Azonafide platform has a unique mechanism of action, Oncolinx can exclusively target slow growing cancers, drug resistant cancers, and other cancers that cannot be treated by the technologies of the two competitors (Seattle Genetics and ImmunoGen).

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores